Amundi’s Zevra Therapeutics ZVRA Stock Holding History

Amundi’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$156K	Buy	+14,198	New	+$168K	﹤0.01%	2016

Other funds holding ZVRA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.28B AUM 15.79% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Retirement Planning Company of New England Warwick, Rhode Island $263M AUM 26.23% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Amundi's ZVRA Position: Q3 2026 in Review

Amundi opened a new position in Zevra Therapeutics (ZVRA) in Q3 2026: 14,198 shares worth $156K. The stake represents ﹤0.01% of the portfolio and ranks #2016 among its holdings.

61 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

Amundi held 14,198 shares of Zevra Therapeutics worth $156K as of Q3 2026.
Zevra Therapeutics was a new Amundi position in Q3 2026.
Zevra Therapeutics made up ﹤0.01% of Amundi's portfolio in Q3 2026, its #2016 holding.
61 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on Amundi's 13F filing for Q3 2026, filed 6 Nov 2026.